Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 10/20 | 0.69 |
| ▸ | CA1 | P00915 | 6/20 | 0.69 |
| ▸ | CA9 | Q16790 | 6/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | CRHBP | P24387 | 1/20 | 0.56 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2992964 | 0.82 | ALDH1A1 (1.00) | GAACA1CA9POLBHPGD | |
| SCHEMBL9121193 | 0.81 | ALDH1A1 (0.73) | GAACA1CA9POLBHPGD | |
| SCHEMBL9220486 | 0.81 | RAB9A (0.67) | GAAPOLBSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL3003231 | 0.81 | ALDH1A1 (0.73) | GAACA1CA9POLBHPGD | |
| SCHEMBL21408728 | 0.81 | RAB9A (0.54) | GAACA1CA9POLBHPGD | |
| SCHEMBL7907958 | 0.80 | GAA (0.72) | GAAPOLBSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL11414330 | 0.80 | GAA (0.70) | GAACA1CA9POLBSMN1; SMN2 | |
| SCHEMBL2995413 | 0.79 | ALDH1A1 (0.75) | GAACA1CA9POLBHPGD | |
| SCHEMBL10652021 | 0.79 | ALDH1A1 (0.68) | GAACA1CA9POLBHPGD | |
| SCHEMBL16642162 | 0.78 | ALDH1A1 (0.67) | GAACA1CA9HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110295016-A1 | A NEW PROCESS FOR PREPARING 4-[4-METHYL-5-(CL-10ALKYLTHIO/C5-10ARYL-CL-6ALKYLTHIO)-4H-1,2,4-TRIAZOL-3-YL]PYRIDINES | ASTRAZENECA AB (SE) | 2011-12-01 | — | — | US | claimed |
| EP-2376474-A1 | A NEW PROCESS FOR PREPARING 4- Ý4-METHYL-5- (CL- 10ALKYLTHIO/C5-10ARYL-CL-6ALKYLTHIO) -4H-1, 2, 4-TRIAZOL-3- YL¨PYRIDINES. | AstraZeneca AB (SE) | 2011-10-19 | — | — | EP | claimed |
| WO-2010068172-A1 | A NEW PROCESS FOR PREPARING 4- [4-METHYL-5- (CL- 10ALKYLTHIO/C5-10ARYL-CL-6ALKYLTHIO) -4H-1, 2, 4-TRIAZOL-3- YL] PYRIDINES. | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | WO | claimed |
| US-20110295016-A1 | A NEW PROCESS FOR PREPARING 4-[4-METHYL-5-(CL-10ALKYLTHIO/C5-10ARYL-CL-6ALKYLTHIO)-4H-1,2,4-TRIAZOL-3-YL]PYRIDINES | ASTRAZENECA AB (SE) | 2011-12-01 | — | — | US | disclosed |
| US-20110295016-A1 | A NEW PROCESS FOR PREPARING 4-[4-METHYL-5-(CL-10ALKYLTHIO/C5-10ARYL-CL-6ALKYLTHIO)-4H-1,2,4-TRIAZOL-3-YL]PYRIDINES | ASTRAZENECA AB (SE) | 2011-12-01 | — | — | US | disclosed |
| US-20110295016-A1 | A NEW PROCESS FOR PREPARING 4-[4-METHYL-5-(CL-10ALKYLTHIO/C5-10ARYL-CL-6ALKYLTHIO)-4H-1,2,4-TRIAZOL-3-YL]PYRIDINES | ASTRAZENECA AB (SE) | 2011-12-01 | — | — | US | disclosed |
| CN-102245592-A | Preparation of 4- [ 4-methyl-5- (C)1-10Alkylthio radicals/C5-10aryl-C1-6Alkylthio) -4H-1 | ASTRAZENECA AB | 2011-11-16 | — | — | CN | disclosed |
| EP-2376474-A1 | A NEW PROCESS FOR PREPARING 4- Ý4-METHYL-5- (CL- 10ALKYLTHIO/C5-10ARYL-CL-6ALKYLTHIO) -4H-1, 2, 4-TRIAZOL-3- YL¨PYRIDINES. | AstraZeneca AB (SE) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010068172-A1 | A NEW PROCESS FOR PREPARING 4- [4-METHYL-5- (CL- 10ALKYLTHIO/C5-10ARYL-CL-6ALKYLTHIO) -4H-1, 2, 4-TRIAZOL-3- YL] PYRIDINES. | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010068172-A1 | A NEW PROCESS FOR PREPARING 4- [4-METHYL-5- (CL- 10ALKYLTHIO/C5-10ARYL-CL-6ALKYLTHIO) -4H-1, 2, 4-TRIAZOL-3- YL] PYRIDINES. | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | WO | disclosed |
| US-7476684-B2 | Compounds for the treatment of neurological, psychiatric or pain disorders | ASTRAZENECA AB (SE) | 2009-01-13 | — | — | US | disclosed |
| US-20070129408-A1 | New compounds for the treatment of neurological, psychiatric or pain disorders | ASTRAZENECA AB (SE) | 2007-06-07 | — | — | US | disclosed |
| US-20070129408-A1 | New compounds for the treatment of neurological, psychiatric or pain disorders | ASTRAZENECA AB (SE) | 2007-06-07 | — | — | US | disclosed |
| US-20070129408-A1 | New compounds for the treatment of neurological, psychiatric or pain disorders | ASTRAZENECA AB (SE) | 2007-06-07 | — | — | US | disclosed |
| WO-2007040982-A1 | 5- (PHENYLISOXAZOLYLETHOXY) -TRIAZOL- 3 -YL SUBSTITUTED PYRIDINE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007040982-A1 | 5- (PHENYLISOXAZOLYLETHOXY) -TRIAZOL- 3 -YL SUBSTITUTED PYRIDINE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| EP-0276793-B1 | 3-ARYL-5-ALKYLTHIO-4H-1,2,4-TRIAZOLES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-06-16 | — | — | EP | disclosed |
| US-4981863-A | ANTIANXIETY | MERRELL DOW PHARMACEUTICALS (US) | 1991-01-01 | — | — | US | disclosed |
| US-4900743-A | TREATING MUSCLE SPASMS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-02-13 | — | — | US | disclosed |
| EP-0276793-A2 | 3-Aryl-5-alkylthio-4H-1,2,4-triazoles | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110295016-A1 | A NEW PROCESS FOR PREPARING 4-[4-METHYL-5-(CL-10ALKYLTHIO/C5-10ARYL-CL-6ALKYLTHIO)-4H-1,2,4-TRIAZOL-3-YL]PYRIDINES | NT5C, CBR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | GAA 4322/4885CA1 2029/4885CA9 1123/4885 |
| US-20070129408-A1 | New compounds for the treatment of neurological, psychiatric or pain disorders | GRIN2C, OPRL1, GRIN2A | GAA 486/4885CA1 2584/4885CA9 4664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.